Abstract
The urokinase receptor (uPAR) was originally identified as the membrane receptor of the serine protease urokinase (uPA), thereby implicated in the plasminogen activation cascade and regulation of pericellular proteolysis. Later on, vitronectin was showed to be another major ligand providing uPAR with a role in cell adhesion. Other unrelated ligands have been subsequently reported including for example factor XII and SRPX2 expanding the functions of uPAR to unexpected biological areas such as the initiation of the coagulation cascade or the regulation of language development. Due to its glycosylphosphatidylinositol (GPI) anchor, uPAR has no intracellular domain and thus exerts its signaling capacity through lateral interactions with other components of the plasma membrane that actually mediate uPAR-induced signals. As yet, a total 42 proteins interacting directly with uPAR can be numbered comprising 9 soluble ligands and 33 lateral partners. The fact that uPAR interacts with members of three major families of membrane receptors i.e. G protein-coupled receptors, receptor tyrosine kinases, and integrins implies that the actual number of components constituting the uPAR interacome is extremely high. For example, 156 factors belong to the integrin adhesome. Moreover, in the light of the wide diversity of the components of the uPAR interactome, uPAR appears to be an essential player of major biological systems including the blood coagulation, complement and plasma kallikrein-kinin cascades. This review describes the soluble ligands and lateral partners of the uPAR interactome, the mechanisms regulating uPAR interactions and their proved and/or potential biological functions.
Keywords: Urokinase receptor/uPAR, cell migration, cell proliferation, cell adhesion, integrin, receptor tyrosine kinase, G protein-coupled receptor, signal transduction, glycosylphosphatidylinositol, zymogen, caveolins, neutropenia, angiogenesis, MAP kinase pathway, cellular signalling
Current Pharmaceutical Design
Title: The Urokinase Receptor Interactome
Volume: 17 Issue: 19
Author(s): Gabriele Eden, Marco Archinti, Federico Furlan, Ronan Murphy and Bernard Degryse
Affiliation:
Keywords: Urokinase receptor/uPAR, cell migration, cell proliferation, cell adhesion, integrin, receptor tyrosine kinase, G protein-coupled receptor, signal transduction, glycosylphosphatidylinositol, zymogen, caveolins, neutropenia, angiogenesis, MAP kinase pathway, cellular signalling
Abstract: The urokinase receptor (uPAR) was originally identified as the membrane receptor of the serine protease urokinase (uPA), thereby implicated in the plasminogen activation cascade and regulation of pericellular proteolysis. Later on, vitronectin was showed to be another major ligand providing uPAR with a role in cell adhesion. Other unrelated ligands have been subsequently reported including for example factor XII and SRPX2 expanding the functions of uPAR to unexpected biological areas such as the initiation of the coagulation cascade or the regulation of language development. Due to its glycosylphosphatidylinositol (GPI) anchor, uPAR has no intracellular domain and thus exerts its signaling capacity through lateral interactions with other components of the plasma membrane that actually mediate uPAR-induced signals. As yet, a total 42 proteins interacting directly with uPAR can be numbered comprising 9 soluble ligands and 33 lateral partners. The fact that uPAR interacts with members of three major families of membrane receptors i.e. G protein-coupled receptors, receptor tyrosine kinases, and integrins implies that the actual number of components constituting the uPAR interacome is extremely high. For example, 156 factors belong to the integrin adhesome. Moreover, in the light of the wide diversity of the components of the uPAR interactome, uPAR appears to be an essential player of major biological systems including the blood coagulation, complement and plasma kallikrein-kinin cascades. This review describes the soluble ligands and lateral partners of the uPAR interactome, the mechanisms regulating uPAR interactions and their proved and/or potential biological functions.
Export Options
About this article
Cite this article as:
Eden Gabriele, Archinti Marco, Furlan Federico, Murphy Ronan and Degryse Bernard, The Urokinase Receptor Interactome, Current Pharmaceutical Design 2011; 17 (19) . https://dx.doi.org/10.2174/138161211796718215
| DOI https://dx.doi.org/10.2174/138161211796718215 |
Print ISSN 1381-6128 |
| Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Multidisciplinary Pharmaceutical Drug Design Strategies in the Progress of Drug Discovery"
The process of developing a drug is time and money-consuming, but also fascinating. The development of numerous computational techniques, synthetic methodologies, formulation-based drug discovery, etc., has improved the drug discovery process. The process of developing new drugs is significantly hampered by drug-poor pharmacodynamics and pharmacokinetic problems. To address these challenges, ...read more
Accelerating Cancer drug discovery using Artificial intelligence and In Silico methods
The Artificial intelligence and in silico methods speed up cancer drug discovery, transforming how new treatments are developed. Artificial intelligence, along with in silico methods, allows for quick investigation of large biological datasets, helping identify potential drug targets with remarkable speed and accuracy. Machine learning models help us understand how ...read more
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Artificial Intelligence and Computational Approaches in Drug Discovery
Computer-aided drug design (CADD) and artificial intelligence (AI) are fundamentally reshaping drug discovery pipelines by significantly enhancing efficiency in molecular screening, rational drug design, and natural product development. In the field of molecular screening, the integration of virtual high-throughput screening with advanced AI models enables rapid analysis of million-compound libraries, ...read more
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacodynamics of Memantine: An Update
Current Neuropharmacology An Update on Parkinson’s Disease and its Neurodegenerative Counterparts
Current Medicinal Chemistry Phytoconstituents of <i>Lantana camara</i> L.: Rekindling Hope in the Cancer Treatment
Current Bioactive Compounds Targeted Radiosensitization in Prostate Cancer
Current Pharmaceutical Design Genomic Expression in the Epileptogenic Hippocampus and Psychiatric Co-Morbidities
Current Psychiatry Reviews Astrocytic Target Mechanisms in Epilepsy
Current Medicinal Chemistry Immunotherapeutic Options for Pediatric Malignancies
Current Immunology Reviews (Discontinued) Limonene and Perillyl Alcohol Derivatives: Synthesis and Anticancer Activity
Mini-Reviews in Medicinal Chemistry Multi-modal Anti-cancer Activities Provided by a Non-replicating Sendai Virus Envelope
Current Cancer Therapy Reviews Targeting the Tumor Stroma with Peroxisome Proliferator Activated Receptor (PPAR) Agonists
Anti-Cancer Agents in Medicinal Chemistry New and Highly Potent Antitumor Natural Products from Marine-Derived Fungi: Covering the Period from 2003 to 2012
Current Topics in Medicinal Chemistry Quantitative Structure – Activity Relationship Study on Saponins as Cytotoxicity Enhancers
Letters in Drug Design & Discovery Radiochemical Evaluation and <i>In Vitro</i> Assessment of the Targeting Ability of a Novel <sup>99m</sup>Tc-HYNIC-RGD for U87MG Human Brain Cancer Cells
Current Radiopharmaceuticals Tumor Stroma Manipulation By MSC
Current Drug Targets Impact of IL-12 in Cancer
Current Cancer Drug Targets EDITORIAL [Hot topic: New Therapeutic Advances and Perspectives in Tumour Angiogenesis (Guest Editor: Eddy Pasquier)]
Current Cancer Drug Targets From the Design to the Clinical Application of Thromboxane Modulators
Current Pharmaceutical Design Cancer Therapy: Targeting Mitochondria and other Sub-cellular Organelles
Current Pharmaceutical Design Editorial [Hot Topic: SOD Enzymes and Their Mimics in Cancer:Pro- vs Anti-Oxidative Mode of Action-Part II (Guest Editor: Ines Batinic-Haberle)]
Anti-Cancer Agents in Medicinal Chemistry Signal Transducer and Activator of Transcription 3 Signaling Pathway: A Potential Target in Sarcoma Treatment
Current Enzyme Inhibition





